Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 717808, 4 pages
http://dx.doi.org/10.1155/2013/717808
Research Article

Serum Interleukin-6 Expression Level and Its Clinical Significance in Patients with Dermatomyositis

Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China

Received 2 May 2013; Accepted 2 August 2013

Academic Editor: Jianying Zhang

Copyright © 2013 Min Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Wu, D. Geng, and J. Xu, “An approach to the development of interstitial lung disease in dermatomyositis: a study of 230 cases in China,” Journal of International Medical Research, vol. 41, no. 2, pp. 493–501, 2013. View at Publisher · View at Google Scholar
  2. M. Fathi, M. Dastmalchi, E. Rasmussen, I. E. Lundberg, and G. Tornling, “Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis,” Annals of the Rheumatic Diseases, vol. 63, no. 3, pp. 297–301, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Tanaka and T. Kishimoto, “Targeting interleukin-6: all the way to treat autoimmune and inflammatory disease,” International Journal of Biological Sciences, vol. 8, no. 9, pp. 1226–1227, 2012. View at Google Scholar
  4. S. M. Hurst, T. S. Wilkinson, R. M. McLoughlin et al., “IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation,” Immunity, vol. 14, no. 6, pp. 705–714, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Atreya, J. Mudter, S. Finotto et al., “Erratum: blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo,” Nature Medicine, vol. 6, no. 5, pp. 583–588, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Kishimoto, “Interleukin-6: from basic science to medicine—40 years in immunology,” Annual Review of Immunology, vol. 23, pp. 1–21, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Gabay, “Interleukin-6 and chronic inflammation,” Arthritis Research and Therapy, vol. 8, supplement 2, article S3, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Bohan and J. B. Peter, “Polymyositis anddermatomyositis (first of two parts),” The New England Journal of Medicine, vol. 292, no. 7, pp. 344–347, 1975. View at Google Scholar · View at Scopus
  9. A. Bohan and J. B. Peter, “Polymyositis and dermatomyositis (second of two parts),” The New England Journal of Medicine, vol. 292, no. 8, pp. 403–407, 1975. View at Google Scholar · View at Scopus
  10. M. C. Hochberg, “Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 40, no. 9, p. 1725, 1997. View at Google Scholar · View at Scopus
  11. D. Aletaha, T. Neogi, and A. J. Silman, “2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative,” Annals of the Rheumatic Diseases, vol. 69, pp. 1580–1588, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Vatajli, S. Bombardiere, R. Jonsson et al., “Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group,” Annals of the Rheumatic Diseases, vol. 61, no. 6, pp. 554–558, 2002. View at Google Scholar
  13. M. C. Dalakas, “Immunopathogenesis of inflammatory myopathies,” Annals of Neurology, vol. 37, supplement 1, pp. S74–S86, 1995. View at Google Scholar · View at Scopus
  14. M. C. Dalakas and R. Hohlfeld, “Polymyositis and dermatomyositis,” The Lancet, vol. 362, no. 9388, pp. 971–982, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Nishimoto, T. Kishimoto, and K. Yoshizaki, “Anti-interleukin 6 receptor antibody treatment in rheumatic disease,” Annals of the Rheumatic Diseases, vol. 59, 1, pp. i21–i27, 2000. View at Google Scholar · View at Scopus
  16. M. Murakami and T. Hirano, “The pathological and physiological roles of IL-6 amplifier activation,” International Journal of Biological Sciences, vol. 8, no. 9, pp. 1267–1280, 2012. View at Google Scholar
  17. F. S. Caravaca, M. V. Martín, S. Barroso, B. Ruiz, and R. Hernández-Gallego, “Do inflammatory markers add predictive information of death beyond that provided by age and comorbidity in chronic renal failure patients?” Nephrology Dialysis Transplantation, vol. 21, no. 6, pp. 1575–1581, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. J. B. Arlet, D. Boutin-Le Thi Huong, J. Pouchot, and J. C. Piette, “Current concepts on the pathogenesis of adult-onset Still's disease,” Revue de Medecine Interne, vol. 26, no. 7, pp. 549–556, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Scuderi, F. Mannella, M. Marino, C. Provenzano, and E. Bartoccioni, “IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis,” Journal of Neuroimmunology, vol. 176, no. 1-2, pp. 9–15, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. B. N. Cronstein, “Interleukin-6-a key mediator of systemic and local symptoms in rheumatoid arthritis,” Bulletin of the NYU Hospital for Joint Diseases, vol. 65, supplement 1, pp. S11–S15, 2007. View at Google Scholar · View at Scopus
  21. A. Ash and P. Emery , “The role of Tocilizumab in the management of rheumatoid arthritis,” Expert Opinion on Biological Therapy, vol. 12, no. 9, pp. 1277–1289, 2012. View at Google Scholar
  22. J. P. Ahluwalia, “Immunotherapy in inflammatory bowel disease,” Medical Clinics of North America, vol. 96, no. 3, pp. 525–544, 2012. View at Google Scholar
  23. A. L. Mammen, “Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis,” Nature Reviews Neurology, vol. 7, no. 6, pp. 343–354, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Yokota, “Interleukin-6 as a pathogenic factor of systemic-onset juvenile idiopathic arthritis,” Nihon Rinsho Meneki Gakkai Kaishi, vol. 31, no. 2, pp. 99–103, 2008. View at Publisher · View at Google Scholar · View at Scopus